Indivior Share News (INDV)

TOP NEWS: Indivior swings to profit as eyes primary listing move to US

(Alliance News) - Shares in Indivior PLC rose on Thursday, after the company said that strong sales of its flagship Sublocade treatment had pushed its revenue to new heights, and it added that it will begin talks with shareholders to move its primary listing across the Atlantic.

Indivior planning to move primary listing to US, shares surge

(Sharecast News) - Indivior surged on Thursday after the opioid addiction treatment maker said it was planning to move its primary listing to the US.

UK earnings, trading statements calendar - next 7 days

London close: Stocks rise as UK inflation slows further

(Sharecast News) - London's stock markets saw a notable upswing on Wednesday, driven by encouraging data revealing a greater-than-anticipated slowdown in UK inflation for November.

LONDON MARKET MIDDAY: Stocks sparkle thanks to UK inflation data

(Alliance News) - Stock prices in London were higher at midday Wednesday, as investors felt the festive cheer thanks to cooler-than-expected inflation data for the UK.

IN BRIEF: Indivior agrees settlement with Actavis over patent dispute

Indivior PLC - Richmond, Virginia-based pharmaceutical firm - Says its subsidiaries Indivior Inc and Indivior UK Ltd has agreed on a settlement deal with Actavis Laboratories UT Inc, a subsidiary of Teva Pharmaceuticals, resolving patent disputes of Actavis's abbreviated new drug application for generic buprenorphine and naloxone sublingual film. Says it has granted Actavis a license to US patent no.11,135,216, allowing it to launch general film products in the US from January 31 2025, unless unexpired patent claims are found to be invalid.

LONDON MARKET OPEN: Stocks feeling festive on UK, US rate cut hopes

(Alliance News) - Stock in London enjoyed a broad-based rally at Wednesday's open, as a surprise UK inflation print boosted risk sentiment, with investors pinning their hopes on UK and US interest rate cuts next year.

Indivior strikes agreement with Actavis over patent dispute

(Sharecast News) - Indivior announced significant agreement in its ongoing patent dispute with Actavis Laboratories UT, a subsidiary of Teva Pharmaceuticals, on Wednesday.

Indivior and Reckitt land legal boost in UK Suboxone claim

(Alliance News) - Indivior PLC and one-time parent Reckitt Benckiser Group PLC were handed a legal victory on Tuesday after the High Court of Justice of England & Wales dismissed a lawsuit related to alleged false marketing of an opioid addiction treatment.

LONDON BROKER RATINGS: Investors told to 'sell' Sage and Deliveroo

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

London close: Stocks mixed ahead of Autumn Statement

(Sharecast News) - London's stock markets saw a mixed performance at the close of trading on Monday, with Ashtead and Compass among the leading losers.

Indivior announces $100m share buyback

(Sharecast News) - Pharma group Indivior has announced a $100m share buyback to reduce its issued shared capital and return cash to shareholders.

UPDATE: Indivior plans up to USD100 million share buyback programme

(Alliance News) - Indivior PLC on Friday announced a new share buyback programme, as it hailed its outlook for medium-term profitable growth.

Indivior to keep Scopia's Jerome Lande on board as agreement extended

(Alliance News) - Indivior PLC on Friday said it changed its existing relationship with Scopia Capital Management LP to keep Scopia representative Jerome Lande on the Indivior board.

Indivior extends deal with investor Scopia to keep boardmember Jerome Lande

(Sharecast News) - Pharma group Indivior has extended its deal with shareholder Scopia Capital Management that will see the latter's representative Jerome Lande stay on the board until the end of next year.